Dear Biotech Frontiers subscribers, One of the most important qualities that separates professional investors from amateurs is the capacity to face reality when it becomes clear an investment thesis has broken down. As I’ve said before, hope is not a strategy. Unfortunately, that moment has come regarding our Biotech Frontiers investment in Iovance Biotherapeutics (Nasdaq:
EchoStar (Nasdaq: SATS) reported its results for the quarter ended March 31. The news pushed up our Hughes Satellite bonds to a price where we recommended selling. Operating profit for the Hughes Satellite business – the business that issued the 5.25% secured bonds maturing August 1, 2026, in the Distressed Investing portfolio – rose 8.1%
In Distressed Investing’s December 2024 issue “Rising From The Ashes,” Marty Fridson and his team recommended buying QVC’s 4.375% bond maturing September 1, 2028, then at $840, up to a price of $860. The bonds currently trade for $878, up 4.5% from the entry price. We liked QVC’s business –- which had been improving –
Dear Biotech Frontiers subscribers, I’m writing to you with two sell recommendations from the Biotech Frontiers portfolio this morning – one driven by good news, the other by bad. Let’s start with the good news. Last July, we recommended TG Therapeutics (Nasdaq: TGTX) with an entry price of $18.79 per share. We suggested that TG
Shares of electrical infrastructure provider Eaton Corp (NYSE: ETN) fell below our stop loss price of $338.83 yesterday. If you haven’t yet sold shares, we recommend exiting the position. We will use the recommended stop loss as the official exit price for our model portfolio. We recommended Eaton on September 18, as part of a
This morning, uniQure (Nasdaq: QURE) – which we originally recommended as part of our basket of 10 negative-EV stocks in January with an entry price of $6.62, and recommended again as a standalone pick in October with an entry price of $4.54 – issued a press release announcing that the company has reached an agreement
Three companies in our Parallel Processing Revolution basket have hit their stop losses – Taiwan Semiconductor Manufacturing (NYSE: TSM), Nvidia (Nasdaq: NVDA), and Vertiv Holdings (NYSE: VRT). We recommended these stocks in The Big Secret on Wall Street on September 18 with a 10% trailing stop loss and a maximum risk rating level of 5,
Dear Readers, Shares of semiconductor chip designer ARM Holdings (Nasdaq: ARM) have dropped below the level of our 10% trailing stop loss. We recommended ARM shares on September 18 at $138, and are following our stop loss recommendation to sell at $134. We will use today’s closing price as the official exit price in our
With shares trading up more than 100% from our entry price, we are recommending selling a half position in Peloton Interactive (Nasdaq: PTON). In our initial report on Peloton, “A Change of Gears,” dated October 11, 2023, we recommended purchasing Peloton’s 0% coupon bonds coming due February 15, 2026. At the time these bonds were
Less than six weeks ago, on Friday, September 6, we recommended buying shares of Sagimet Biosciences (Nasdaq: SGMT). Since we published our report, Sagimet’s management has appeared at several institutional-investor conferences and has also released a fuller data set confirming its blockbuster Phase II clinical trial results for the company’s lead drug candidate denifanstat. Yesterday,